Accumulating evidence reveals a significant correlation between angiopoietin 2 (Ang2) expression and tumor invasion and metastasis in various human cancers, but the major focus of recent studies has been on the angiogenic effects of Ang2. We recently reported that Ang2-stimulated glioma cell invasion results from the up-regulation and activation of matrix metalloprotease 2 (MMP-2) in tumor cells. In this study, we identify a novel mechanism by which Ang2 stimulates MMP-2 expression leading to glioma cell invasion. We show that Ang2 interacts with A v
Introduction
Angiopoietin 2 (Ang2), a known angiogenic regulator, plays important roles in angiogenesis and tumor progression (1) . Ang2, expressed in both endothelial cells and tumor cells, has been significantly correlated with tumor metastasis and invasion (2-6), but the mechanism by which Ang2 acts on tumor cells remains obscure. The highly conserved COOH-terminal fibrinogen-like domain of the angiopoietins implies a functional association with the integrin receptor family (7, 8) . Integrins are crucial for migration and invasion of tumor cells, not only for mediating adhesion of tumor cells to the extracellular matrix but also for regulating the processes of cell migration and invasion (9) . Integrins are heterodimeric glycoproteins composed of one a chain and one h chain. The h 1 family of integrins associates with at least one of the 12 a-chains (a 1 -a 11 and a v ) representing the major group of cellular extracellular matrix receptors. h 1 -Integrin promotes metastasis of h 1 -null tumor cells (9) . Mutation of the intracellular domain of h 1 integrin differentially affects cell adhesion, invasion, and metastasis (10) . Ang2, as well as other members of the angiopoietin family, is a potential substrate for the integrin receptor family in endothelial cells, fibroblasts, and myocytes (11) (12) (13) . Ang2 not only enhances cell adhesion in both endothelial cells and Tie2-deficient fibroblasts but also triggers integrin-mediated intracellular signal transduction pathways in these cells.
Malignant human gliomas are pathophysiologically characterized by their insidious infiltration of the brain (14) . Invasion of glioma cells into adjacent brain structures occurs through the activation of multigenic programs, including matrix metalloproteases (MMP) such as MMP-2, which degrade extracellular matrix to overcome the extracellular matrix barrier at the invasive fronts of tumors (15) . Several reports have recently shown that upregulation of MMP-2 correlates with the invasiveness of human gliomas (16) (17) (18) . Interestingly, integrin-mediated signaling pathways are involved in regulation of MMP-2 expression and cell invasion in tumor cells (19) . Expression patterns of several integrins are correlated with invasive and migratory behaviors in glioma cells in vitro and in vivo (17) . MMP-2 expression and tumor cell invasion have also been associated with the activation of downstream regulators of integrins such as focal adhesion kinase (FAK), p130
Cas , extracellular signal-regulated protein kinase (ERK)/ mitogen-activated protein kinase, and c-jun NH 2 -terminal kinase (JNK)/stress-activated protein kinase (20, 21) . We recently reported that coexpression of Ang2 with MMP-2 was found in the invasive areas, but not in the central regions, of primary human glioma specimens (16, 18) . Stable expression of Ang2 by glioma cells leads to an increase in glioma cell invasiveness in vitro as well as in murine intracranial xenografts accomplished through upregulation and activation of MMP-2 (16) .
In this study, we characterize the mechanism by which Ang2 induces glioma cell invasion by stimulating MMP-2 expression and secretion in glioma cells. We show that Ang2 interacts with a v h 1 integrin in U87MG glioma cells, resulting in the activation of FAK, p130 Cas , ERK1/2, and JNK, thereby enhancing MMP-2 expression and secretion. As a functional consequence of increased MMP-2 secretion, glioma cell invasion is promoted. Furthermore, stable expression of dominant-negative forms of FAK or p130
Cas in glioma cells inhibits Ang2-stimulated MMP-2 expression and secretion by anti-h 3 (B3A), anti-a 3 , anti-a 5 , and anti-a v integrin antibodies that were included in the a integrin blocking investigator kit, anti-Myc (9B11), and anti-Ang2 antibodies], and then collected with 50 AL of either a Protein G-plus or a Protein G-plus/Protein A agarose bead slurry. The eluted proteins from Ni + -NTA beads or the antibody-complexed proteins from coimmunoprecipitation were subjected to SDS-PAGE under reducing conditions and detected with an anti-h 1 integrin (JB1A) or an anti-Ang2 antibody.
Gelatin zymography and in vitro invasion assays. Zymographic analyses for MMP-2 and in vitro invasion assays were done as previously described (16) .
Intracranial brain tumor xenografts and immunohistochemistry. Stereotactic implantation of various types of U87MG cells, sacrifice of glioma-bearing mice, tumor processing, and analyses of intracranial U87MG glioma invasiveness were done as previously described (16) .
Results
Ang2-enhanced adhesion of Tie2-deficient glioma cells is mediated by integrins. We first used FACS, immunoblot, and reverse transcription-PCR (RT-PCR) analyses (see Supplementary materials) to assess the expression of 11 integrin subunits and complexes that have been implicated in cancer cell migration and invasion (19) . RT-PCR analyses were done to further confirm the absence of the particular integrin subunits in U87MG cells that had shown negative results by immunoblot analysis. We found that h 1 , h 3 , a 2 , a 3 , a 5 , a v , a 6 , a v h 3 , and a v h 5 are expressed in U87MG cells whereas the expression of h 4 , a 1 , and a 4 in U87MG cells was undetectable (Supplementary Table S1 ). Then, we purified recombinant Ang2 from the CM of U87MG/Ang2-expressing (U87MG/ Ang2) cells using Ni + -NTA affinity chromatography, achieving an f60-fold increase in Ang2 protein concentration with 90% purity (data not shown). The biological activity of the purified Ang2 was verified by competitive inhibition of Ang1-stimulated tyrosine phosphorylation of Tie2 in endothelial cells (16) .
Next, we assessed whether Ang2 stimulates U87MG cell adhesion and which integrin subunit is involved in Ang2-stimulated cell adhesion and motility. As shown in Supplementary Fig. S1 , U87MG cells tightly adhered to the Ang2-coated surface compared with the BSA-coated surface. A general integrin blocking reagent, EDTA caused complete inhibition of U87MG cell adherence to Ang2, and a RGD peptide showed more potent inhibitory effect when compared with a RAD peptide. We also assessed whether the integrin receptors expressed in U87MG glioma cells (Supplementary Table S1 ) are involved in Ang2-stimulated cell adhesion by preincubating the cells with functional blocking integrin antibodies.
Among these functional blocking antibodies, only an anti-h 1 antibody caused complete inhibition of U87MG cells adhering to Ang2 compared with mouse IgG control. Furthermore, anti-h 3 , anti-a 2 , anti-a 3 , anti-a 5 , anti-a 6 , and anti-a v antibodies blocked Ang2-stimulated U87MG cell adhesion to a lesser degree compared with the anti-h 1 antibody. These data suggest that interaction of Ang2 with integrins is involved in Ang2-stimulated U87MG cell adhesion and h 1 , h 3 , a 3 , a 5 , and a v integrins are likely involved in this adhesion process.
Ang2 associates with B 1 , A 5 , and A v integrins in Tie2-deficient human glioma cells. To evaluate whether Ang2 is associated with h 1 , h 3 , a 3 , a 5 , and a v integrins in Tie2-deficient glioma cells, we did pull-down and coimmunoprecipitation assays that have been used to identify integrin-associated proteins (23) . Integrin subunits h 1 , a 5 , a v , but not h 3 , a 3 , and Ang2, were detected in the pull-down portion by immunoblot analyses of U87MG cells that had been incubated with serum-free CM of U87MG/Ang2-expressing cells (CM/Ang2; Fig. 1A ). In contrast, these integrins and Ang2 were undetectable in the pull-down portion from the cells that were incubated with the serum-free CM of U87MG cells (CM/ control) whereas these integrins were found in the total U87MG cell lysates without exposure to CM. In the immunoprecipitation assays, equal amounts of h 1 integrin proteins in the immunoprecipitated complexes from both groups were seen by immunoblot analysis, but Ang2 was only present in the immunoprecipitated complexes from the U87MG cells incubated with CM/Ang2 (Fig. 1B, a) . In parallel immunoprecipitation experiments using an anti-Myc antibody or an anti-Ang2 antibody, only the immunoprecipitates from U87MG cells exposed to CM/Ang2 reacted strongly with an anti-h 1 antibody (Fig. 1B, b and c) .
A v B 1 integrin mediates Ang2-stimulated tyrosine phosphorylation of FAK and p130
Cas . We analyzed whole-cell lysates by immunoblot analyses with an anti-phosphotyrosine antibody. As shown in Fig. 2A , increased tyrosine phosphorylation (pTyr) of proteins with molecular weights in the range of 105 to 160 kDa and 70 kDa was observed in the U87MG cells adherent to Ang2. Anti-h 1 and anti-a v antibodies attenuated the Ang2-enhanced tyrosine phosphorylation of proteins in U87MG cells whereas the anti-h 3 , anti-a 3 , and anti-a 5 antibodies had no effect on tyrosine phosphorylation. We also found that tyrosine phosphorylation of proteins in Ang2 stably transfected U87MG cells was constitutively up-regulated, which may explain why these cells adhere to cell culture plates in a more robust fashion than parental U87MG cells. These results suggest that the a v h 1 integrin may be the principal integrin receptor that is involved in Ang2-stimulated tyrosine phosphorylation of multiple proteins in U87MG cells.
We then assessed whether Ang2 stimulates tyrosine phosphorylation of FAK and p130
Cas through the association with a v h 1 integrin in U87MG cells. As shown in Fig. 2B , the extent of phosphorylation of FAK was enhanced in U87MG cells seeded onto Ang2 as compared with BSA, whereas phosphorylation of p130 Cas was dramatically induced in the cells plated onto Ang2. Pretreatment of U87MG cells with neutralizing anti-h 1 or anti-a v antibodies inhibited phosphorylation of both proteins enhanced by Ang2 compared with the control (mouse IgG) whereas inhibition of h 3 and a 5 had little or no effect. These results indicate that Ang2 stimulates tyrosine phosphorylation of FAK and p130
Cas through a v h 1 integrin in U87MG cells.
Next, we established U87MG cell clones that stably expressed FAK-related nonkinase (FRNK, an endogenous FAK inhibitor; ref. 24) or its mutant form, FRNK S-1034, in U87MG cells or U87MG/Ang2 cells (Fig. 2C ). Expression of FRNK or FRNK S-1034 in U87MG or U87MG/Ang2 cells did not result in any changes in cell morphology, cell growth rate, or expression levels of Ang2 compared with that of parental U87MG or U87MG/Ang2 cells (data not shown). Compared with Ang2-treated U87MG cells, decreased tyrosine phosphorylation of FAK and p130
Cas was seen in FRNKexpressing cell clones (F19, Ang2-F1; Fig. 2D ). Interestingly, expression of FRNK in U87MG and U87MG/Ang2 cells suppressed Ang2-stimulated tyrosine phosphorylation of FAK at amino acids Tyr397 and Tyr861. As expected, FRNK S-1034 expression (S11 or Ang2-S10) did not affect Ang2-induced tyrosine phosphorylation of Tyr861 of FAK and p130
Cas . These results show that adhesion to Ang2 increases tyrosine phosphorylation of FAK and p130
Cas in U87MG cells and Ang2-induced tyrosine phosphorylation of p130
Cas is mediated through FAK activation.
Ang2 activates JNK1 and ERK1/2 through the
Cas signaling pathway. We examined the activation of JNK1 and ERK1/2 in U87MG cells adhering to Ang2. As shown in Fig. 3A , increased phosphorylation of both JNK1 and ERK1/2 in U87MG cells was observed as early as 20 minutes and peaked between 40 and 60 minutes after the cells adhered to Ang2. The Ang2-stimulated activation of JNK1 and ERK1/2 in U87MG cells was mediated by a v h 1 integrin because inhibition of a v or h 1 , but not a 5 or h 3 , attenuated the phosphorylation of both JNK1 and ERK1/2 compared with control mouse IgG ( Fig. 3C and D) . The Ang2 stimulation of JNK1 and ERK1/2 in U87MG cells was also specific because a JNK inhibitor, SP600125 ( Fig. 3C ; ref. 25) , and an ERK1/2 inhibitor, U0126 ( Fig. 3D ; refs. 26, 27) , completely blocked the protein phosphorylation induced by Ang2 compared with the controls.
Next, we determined whether p130 Cas is an important mediator of the Ang2/a v h 1 /FAK signaling pathway by expressing the Src homology 3 (SH3) domain of p130
Cas (CasSH3) in U87MG cells.
CasSH3 binds to FAK and inhibits endogenous p130
Cas binding, thus acting in a dominant-negative manner (28) . Expression of CasSH3 in U87MG cells suppressed Ang2-stimulated tyrosine phosphorylation of p130 Cas (Fig. 3B ) but did not cause any morphologic changes or alteration in cell growth rate compared with U87MG parental cells (data not shown).
Because JNK1 and ERK1/2 are potential downstream effectors of FAK and p130
Cas in mediating cell motility and invasion (21), we tested whether expression of CasSH3 or FRNK in U87MG cells blocks Ang2-stimulated activation of JNK1 and ERK1/2. Expression of FRNK (F19) or CasSH3 (C8) in U87MG cells inhibited Ang2-stimulated activation of both JNK1 (Fig. 3C ) and ERK1/2 ( Fig. 3D ) compared with controls (mouse IgG, DMSO, and a FRNK S-1034-expressing cell clone, S11). In parallel, expression of FRNK in U87MG/Ang2 cell clones (Ang2-F1 and Ang2-F7) also attenuated Ang2-stimulated activation of JNK1 and ERK1/2 when compared with parental U87MG/Ang2 cells or U87MG/Ang2/FRNK S-1034 cell clones, Ang2-S2 and Ang2-S10 (data not shown). These data suggest that Ang2 activates JNK1 and ERK1/2 in U87MG cells and the activation is mediated by the Ang2/a v h 1 integrin/FAK/p130 Cas signaling pathway.
Ang2 stimulates MMP-2 expression and secretion via
Cas -mediated activation of ERK1/2 and JNK1. We examined whether stimulation of MMP-2 by Ang2 is mediated by the a v h 1 integrin/FAK/p130
Cas signaling pathway through activation of JNK1 and ERK1/2 in glioma cells. As shown in Fig. 4A , an increased amount of pro-MMP-2 (72 kDa) was detected in the serum-free CM of U87MG cells plated onto Ang2-coated plates by gelatin zymography and immunoblot analyses in a concentration-dependent manner compared with the cells seeded onto BSA-coated plates. The active form of MMP-2 (64 kDa) was almost undetectable in the CM of U87MG cells plated either on Ang2 or BSA, probably due to insufficient MMP-2 activation resulting from a short period of cell culture (18 hours). Inhibition of h 1 or a v , but not a 5 , by neutralizing antibodies significantly suppressed Ang2-stimulated MMP-2 secretion (Fig. 4B) . Both SP600125 and U0126 also effectively inhibited Ang2-stimulated MMP-2 secretion in U87MG cells (Fig. 4B) .
We next assessed whether inhibition of FAK and p130
Cas by FRNK and CasSH3 blocks Ang2-stimulated MMP-2 expression and secretion (Fig. 4C) . We found that MMP-2 expression and secretion were decreased in U87MG/FRNK-expressing cell clones A, whole-cell lysates from U87MG cells, U87MG/Ang2-expressing cells, and the U87MG cells seeded onto Ang2-coated plates with preincubation using mouse IgG, anti-h 1 , anti-h 3 , anti-a 3 , anti-a 5 , and anti-a v antibodies were analyzed by immunoblot using anti-pTyr or anti-FAK antibodies. These anti-integrin antibodies were used to block Ang2-induced cell adhesion ( Supplementary Fig. S1 ) and examine the involvement of these integrins in Ang2-stimulated glioma cell invasion. Arrows, top, enhanced tyrosine phosphorylation of cellular proteins. Arrow, bottom, FAK protein as a loading control. B, U87MG cells with or without pretreatment using anti-h 1 , anti-h 3 , anti-a 5 , and anti-a v integrin antibodies or mouse IgG were seeded onto BSA-or Ang2-coated plates. FAK or p130
Cas was immunoprecipitated with anti-FAK and anti-p130 Cas antibodies and analyzed by immunoblot using an anti-pTyr antibody. Equal protein expression was verified by reprobing the blots with anti-FAK or anti-p130
Cas antibodies. C, expression of HA-tagged FRNK and FRNK S-1034 in U87MG/FRNK-expressing (F19), U87MG/FRNK S-1034-expressing (S11), U87MG/Ang2 and FRNK-expressing (Ang2-F1), and U87MG/ Ang2 and FRNK S-1034-expressing (Ang2-S10) cell clones were characterized by immunoblot using an anti-HA antibody. D, tyrosine phosphorylation of FAK, pY397-FAK, pY861-FAK, and p130
Cas in U87MG, F19, Ang2-F1, S11, and Ang2-S10 cells that were plated onto BSA-or Ang2-coated surfaces were immunoprecipitated with anti-FAK and anti-p130
Cas antibodies and analyzed by immunoblot using anti-pTyr, anti-pY397-FAK, and anti-pY861-FAK antibodies. Equal protein expression was verified by reprobing the blots with anti-FAK or anti-p130
Cas antibodies. Representative of three independent experiments.
(F13 and F19) and U87MG/CasSH3-expressing cell clones (C3 and C8) compared with parental U87MG cells or U87MG/FRNK S-1034-expressing cell clones (S11 and S21) exposed to Ang2. Lastly, we determined whether Ang2 stimulates MMP-2 secretion via h 1 integrin in other Tie2-deficient human glioma cell lines. As shown in Fig. 4D , preincubation of T98G, U251MG, and U373MG glioma cells with an anti-h 1 antibody significantly inhibited Ang2-stimulated MMP-2 secretion. Additionally, expression of MMP-2 in U87MG cells exposed to various treatments was also assessed with immunoblot analyses using an anti-MMP-2 antibody. The detected levels of expression of MMP-2 were correlated to the amounts of secretion of MMP-2 in the CM by the gelatin zymographic analyses (Fig. 4A-D) . Taken together, our results show that Ang2 is capable of stimulating the expression and secretion of MMP-2 in Tie2-deficient glioma cells through a v h 1 integrin/FAK/p130
Cas -mediated activation of ERK1/2 and JNK1. Interestingly, we could not detect MMP-9 by gelatin zymography from CM of the various cells after an 18-hour cell culture with the various treatments, suggesting that MMP-9 is not involved in Ang2-stimulated human glioma invasion nor regulated by the Ang2/a v h 1 integrin/FAK/p130
Cas /ERK1/2 and JNK1 signaling pathway (data not shown).
Ang2 stimulates cell invasion via the
Cas signaling pathway through ERK1/2 and JNK1 activation. To determine whether Ang2 stimulation of the a v h 1 integrin/FAK/p130
Cas signaling pathway leads to increased U87MG glioma cell invasion, we did in vitro cell invasion assays. As shown in Fig. 5A , exposure to exogenous Ang2 promoted cell invasion whereas Ang2-stimulated cell invasion was blocked by a MMP inhibitor (MMPi-III, 50 Amol/L) that preferentially attenuates MMP-2 activity (Calbiochem; ref. 16 ), anti-h 1 and anti-a v antibodies (25 Ag/mL), SP600125 (25 Amol/L), and U0126 (25 Amol/L) compared with cells treated with mouse IgG or DMSO. Expressing FRNK (F13 and F19) and CasSH3 (C3 and C8) in U87MG cells also suppressed Ang2-stimulated cell invasion compared with parental U87MG cells or U87MG/FRNK S-1034-expressing cells (S11 and S21).
Next, we assessed whether inhibition of h 1 , a v integrin, FAK, JNK1, ERK1/2, and MMP-2 in U87MG/Ang2-expressing cells (Ang2) suppresses Ang2-induced cell invasion. As shown in Fig. 5B , FRNK expression in U87MG/Ang2 expressing cells (Ang2-F1 and Ang2-F7) effectively suppressed Ang2-stimulated cell invasion compared with U87MG/Ang2-expressing cells (Ang2) and U87MG/Ang2/FRNK S-1034-expressing clones (Ang2-S2 and Ang2-S10). Similar to the results with parental U87MG cells seeded on an Ang2-coated surface described in Fig. 4A , pretreatment of U87MG/Ang2-expressing cells with MMPi-III (50 Amol/L), antih 1 and anti-a v antibodies (25 Ag/mL), SP600125 (25 Amol/L), or U0126 (25 Amol/L) also inhibited the cell invasion enhanced by expressing Ang2 in U87MG cells (Fig. 5B ). These data suggest that both the a v h 1 integrin/FAK/p130
Cas /ERK1/2 and JNK1 signaling pathway and MMP-2 are involved in Ang2-stimulated glioma cell invasion.
Inhibition of FAK suppresses Ang2-stimulated MMP-2 expression and glioma invasion in vivo. Lastly, a glioma xenograft model in the murine brain was employed to determine whether inhibition of FAK by FRNK expression could inhibit Ang2-stimulated glioma cell infiltration in vivo. As shown in Fig. 6 , mice that received U87MG/Ang2-expressing cells developed invasive gliomas (Fig. 6B) . The U87MG/Ang2-expressing cells that additionally express FRNK did not exhibit an invasive phenotype and formed well-circumscribed gliomas (Fig. 6C) , which are analogous to U87MG/LacZ-expressing tumors (Fig. 6A) . In contrast, the expression of FRNK S-1034 in U87MG/Ang2-expressing cells (Ang2-S2 and Ang2-S10) was unable to inhibit Ang2-stimulated invasion (Fig. 6D ). Immunohistochemical and immunoblot analyses using anti-Ang2 and anti-MMP-2 antibodies show that expression of FRNK or FRNK S-1034 had no affect on Ang2 expression (Fig. 6G and H) compared with that of U87MG/ Ang2-expressing tumors (Fig. 6F) . However, FRNK expression did noticeably reduce the MMP-2 expression (Fig. 6K ) compared with that of U87MG/Ang2 expressing tumors (Fig. 6J) whereas there was no inhibition of MMP-2 expression by FRNK S-1034 (Fig. 6L) . Immunoblot analyses confirmed that expression of FRNK or FRNK S-1034 by these cell clones did not alter expression levels of Ang2 but FRNK expression did inhibit Ang2-stimulated MMP-2 expression compared with that in U87MG/ Ang2-expressing cells (data not shown). The sensitivity of Cas signaling in glioma cells. U87MG (A and B ), U87MG, C3, C8, F13, F19, S11, S21 (C ), T98G, U251MG, and U373MG cells (D ) were preincubated in the absence or presence of 25 Ag/mL anti-h 1 , anti-a 5 , and anti-a v antibodies, mouse IgG, 25 Amol/L SP600125, and 25 Amol/L U0126 or DMSO and seeded onto plates coated with 10 Ag/mL BSA or Ang2. MMP-2 secretion in the CM of 18-hour cultures was analyzed by zymographic assays. Whole-cell lysates were analyzed by immunoblot assays using an anti-MMP-2 antibody. Immunoblots for h-actin were used as a protein loading control. The experiments were done at least three independent times with similar results. detecting MMP-2 expression in established U87MG gliomas by immunohistochemical staining (Fig. 6I to L) is lower than that in cultured U87MG cells by zymographic and Western blot assays (Fig. 4A-C) . Expression of HA-tagged FRNK and FRNK S-1034 by U87MG/Ang2-expressing cells in vivo was detected by immunohistochemistry using an anti-HA tag antibody (Fig. 6M  and N) . Furthermore, although expression of FRNK, but not FRNK S-1034, in U87MG/Ang2-expressing cells inhibited Ang2-stimulated glioma cell invasion in vitro and in vivo, no alteration of tumor formation of intracranial gliomas formed by either U87MG/Ang2/FRNK-expressing or U87MG/Ang2/FRNK S-1034-expressing cells was observed. Together, these results show that inhibition of FAK by FRNK in U87MG/Ang2-expressing cells suppressed Ang2-stimulated MMP-2 expression and glioma cell infiltration in vivo. (30) in regulating pulmonary inflammation and fibrosis. VEGF 165 and VEGF 189 promote endothelial cell adhesion, migration, and survival through interaction with several integrins independent of VEGF receptors (31) . Fibrinogen has been shown as a ligand for several integrins including the a 5 h 1 integrin receptor (32) . Members of the angiopoietin family contain a fibrinogen-like domain at the COOH terminus of their proteins (8, 33) , suggesting integrins as potential candidate receptors (7) . Adhesion of Tie2-deficient cells, such as fibroblasts and skeletal myocytes, to Ang2-coated as well Ang1-coated surfaces was recently shown (11, 12) . Lacking Tie2 receptors, fibroblasts and myocytes adhere to Ang2-or Ang1-coated surfaces and the adhesion is sensitive to the inhibition of h 1 , h 3 , a 6 , and a v integrins. Interactions of Ang1 and/or Ang2 with these integrins activate FAK and ERK1/2, increasing cell adhesion (11) , and Akt, FAK, and ERK1/2, promoting cell survival (12) . Even in endothelial cells, Ang1 is able to mediate selectively a 5 h 1 integrin outside-in FAK activation, leading to a cross-talk of Tie2 and a 5 h 1 , and fine-tuning modulation of the vascular effect (13) . In this study, we report that Ang2 associates with a v h 1 integrin in Tie2-deficient glioma cells. We observed that Ang2 induces extracellular adhesion and activates intracellular signal transduction pathways in glioma cells. Pull-down and immunoprecipitation assays showed that a v h 1 integrin could be copu-rified with Ang2. The association of Ang2 with a v h 1 integrin was highly calcium and manganese dependent in both pull-down and coimmunoprecipitation assays, suggesting the association of Ang2 with a v h 1 integrin is similar to that of Ang1, Ang2 to various integrins (12) , and PG-MV/vesican with h 1 integrin (23) . Our data further show that Ang2 stimulates a v h 1 integrin/FAKmediated signaling, leading to an increase in MMP-2 expression and glioma cell invasion.
Discussion
FAK and p130 Cas are involved in early integrin receptor signaling. Up-regulated FAK expression and activation have been found in various types of human cancers. An increase of FAK phosphorylation on Tyr397 and Tyr861 strongly correlates with the acquisition of an invasive phenotype of tumor cells (21, 34) . We found that Ang2 stimulates FAK tyrosine phosphorylation on these two tyrosine residues in U87MG cells. Expression of FRNK, but not its mutant form FRNK S-1034, suppressed Ang2-induced activation of FAK/p130
Cas /ERK1/2 and JNK1, MMP-2 expression and secretion, and cell invasion in vitro and reversed the phenotype of Ang2-stimulated glioma cell infiltration and MMP-2 expression in vivo. These results are consistent with previous reports that FAK Tyr397 phosphorylation is required to promote JNK activation and cell invasion by v-Src (35) and that FRNK expression suppressed Src-stimulated Try861 phosphorylation, inhibiting Src activation of FAK downstream signaling, MMP-2 expression, and tumor metastasis (25) . Moreover, FRNK overexpression disrupts focal adhesion and induces anoikis in ventricular myocytes by inhibiting endothelin-1-induced phosphorylation of proline-rich tyrosine kinase 2 (PyK2; ref. 36) . In glioma cells, PyK2 plays critical roles in cell migration. Overexpression of PyK2 stimulates glioma cell migration whereas inhibition of PyK2 by FRNK expression or siRNA for PyK2 significantly inhibits glioma cell migration (37, 38) . Therefore, it is plausible that in addition to suppression of FAK, FRNK expression in U87MG/Ang2-expressing cells also inhibits PyK2 activation, leading to decreased Ang2-induced glioma cell invasion in vitro and in vivo. Cas signaling pathways activates ERK1/2 and JNK1 (19), MMP-2 secretion, and cell invasion (25, 35, 40, 41) . Our results identify an a v h 1 integrin/FAK/p130
Cas /ERK1/2 and JNK1 signaling pathway that mediates Ang2-stimulated MMP-2 expression, secretion, and cell invasion. Functional blocking antibodies for Ang2 and a v and h 1 integrins inhibited Ang2 stimulation of ERK1/2 and JNK. FRNK and CasSH3 or inhibitors for ERK1/2 (U0126) and JNK1 (SP600125) suppressed Ang2 activation of ERK1/2 and JNK1. Furthermore, Ang2-stimulated MMP-2 expression and cell invasion were attenuated by a v and h 1 inhibition, FRNK, CasSH3, U0126, and SP600125. These results are consistent with previous findings that both ERK1/2 and JNK mediate Src-stimulated v-Src3T3 cell invasion and FRNK inhibits v-Src-stimulated phosphorylation of ERK1/2 and JNK (25) . Moreover, our results differ from a study showing that only JNK1 activation, and not ERK1/2 phosphorylation, is required in v-Src-stimulated FAK-Src-p130
Cas signaling in FAK-null fibroblasts (35) .
h 1 -Integrin has been shown to activate FAK-mediated signaling pathways leading to promotion of invasion of various types of human carcinoma cells (10, 42, 43) . Suppression of h 1 expression in rat C6 glioma cells prevented diffuse glioma cell invasion in the brain (44) . On the other hand, several a integrin subunits that associate with the h 1 integrin subunit, such as a v , a 5 , and a 6 integrins, have been implicated in mediating tumor cell invasion (19, 42, 43) . In addition, a v h 3 integrin is also associated with invasion of human gliomas (17, 45) . In our study, we show that a v h 1 , but not other integrin receptors, is associated with Ang2-stimulated glioma cell invasion. Moreover, we cannot rule out other molecules involved in Ang2-stimulated glioma cell invasion. For example, Ang2 may associate with a v h 5 integrin because functional blocking of a v , a 5 , h 1 , h 3 , and a v h 5 inhibited fibroblast or myocyte adhesion to Ang2 (11, 12) . ANGPTL3 and tenascin C interact with a v h 3 integrin through the fibrinogen-like domain that is also present in Ang2 (7, 8) . We found that a 3 and h 3 are not associated with Ang2 whereas a 5 is weakly associated with Ang2. However, inhibition of a 3 , a 5 , and h 3 only moderately suppressed Ang2-mediated cell adhesion (Supplementary Table S1 and Fig. S1 ), but not phosphorylation of FAK and p130
Cas (Fig. 2) . Thus, a v h 3 and a 5 h 1 integrins are probably not involved in Ang2-stimulated glioma cell invasion in our model. Additionally, we have recently reported that MT1-MMP, laminin-5 g2, and Ang2 are coexpressed in the invasive regions, but not in the central areas, of primary glioma specimens and exogenous Ang2 stimulates expression and activation of both MT1-MMP and laminin-5 g2 in U87MG/Ang2-expressing glioma xenografts in the murine brain and in vitro (18) . Taken together, these results warrant further investigation to determine other signaling pathways involved in Ang2-induced glioma cell invasion.
In summary, this study identifies a novel molecular mechanism by which Ang2 stimulates human glioma cell invasion via the a v h 1 integrin/FAK/p130
Cas /ERK1/2 and JNK1 signaling pathway and MMP-2 expression (Supplementary Fig. S2 ). Considering the fact that Ang2 expression has significant links to tumor invasion and metastases in various types of human cancers (2-6), our studies provide a basis for further characterization of the molecular cascades involved in Ang2-stimulated glioma invasion, which may yield promising insight for the development of new diagnostic and therapeutic applications for invasive tumors.
